Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	52.33	75.22	83.16	61.9	173.31	183.35
Short-Term Investments	220.79	217.26	365.54	455.42	283.99	644.56
Cash & Short-Term Investments	273.12	292.48	448.7	517.32	457.3	827.91
Cash Growth	-38.57%	-34.82%	-13.26%	13.12%	-44.76%	56.05%
Other Receivables	1.7	1.9	1.7	3.3	6	6.6
Receivables	1.7	1.9	1.7	3.3	6	6.6
Prepaid Expenses	7.84	9.01	8.72	8.2	8.02	10.62
Total Current Assets	282.66	303.39	459.12	528.82	471.32	845.13
Property, Plant & Equipment	120.82	131.26	163.18	196.43	181.02	160.14
Long-Term Investments	29.51	80.67	3.65	79.47	370.18	207.95
Other Long-Term Assets	37.6	33.39	16.9	16.86	16.11	14.62
Total Assets	470.59	548.71	642.84	821.58	1,039	1,228
Accounts Payable	4.85	5.39	5.9	13.89	10.26	10.39
Accrued Expenses	19.07	21.55	21.98	29.73	29.65	29.83
Current Portion of Leases	7.76	7.51	6.78	6	3.2	2.97
Current Unearned Revenue	-	-	0.09	0.1	0.42	38.99
Other Current Liabilities	-	1.07	2.34	4.02	4.65	12.13
Total Current Liabilities	31.68	35.52	37.08	53.73	48.17	94.32
Long-Term Leases	79.24	83.25	88.35	95.12	69.93	50.81
Other Long-Term Liabilities	10.52	7.76	5.18	5.85	4.13	3.08
Total Liabilities	126.03	126.53	130.6	154.7	122.23	148.21
Common Stock	0.22	0.21	0.17	0.14	0.14	0.14
Additional Paid-In Capital	2,275	2,242	2,075	1,912	1,822	1,726
Retained Earnings	-1,930	-1,820	-1,562	-1,235	-903.35	-646.34
Comprehensive Income & Other	-0.05	-0.09	-0.96	-9.93	-2.57	0.27
Shareholders' Equity	344.56	422.18	512.23	666.88	916.41	1,080
Total Liabilities & Equity	470.59	548.71	642.84	821.58	1,039	1,228
Total Debt	87	90.76	95.12	101.12	73.13	53.78
Net Cash (Debt)	186.12	201.72	353.58	416.2	384.17	774.13
Net Cash Growth	-46.88%	-42.95%	-15.05%	8.34%	-50.37%	62.12%
Net Cash Per Share	0.87	1.04	2.25	2.91	2.83	6.43
Filing Date Shares Outstanding	221.88	217.26	169.09	144.5	142.75	140.65
Total Common Shares Outstanding	220.13	212.21	168.64	144.44	142.62	140.47
Working Capital	250.98	267.86	422.04	475.1	423.15	750.81
Book Value Per Share	1.57	1.99	3.04	4.62	6.43	7.69
Tangible Book Value	344.56	422.18	512.23	666.88	916.41	1,080
Tangible Book Value Per Share	1.57	1.99	3.04	4.62	6.43	7.69
Machinery	37.72	40.47	41.94	41.15	37.96	31.29
Construction In Progress	-	-	-	0.03	0.04	68.94
Leasehold Improvements	108.1	108.13	108.62	108.55	108.35	31.52

Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q